| Description |
The EpiCov study is a French, prospective, random population-based, socio-epidemiological cohort set up in April 2020. Individuals aged 15 years or older living in France (excluding people living in residences for elderly and living in jail) were randomly selected from the national Fichiers démographiques sur les logements et les individus (FIDELI) administrative sampling frame. Among the 134 391 people who responded the first round in May-June 2020, 107 759 responded to the second round in October-December 2020, and among them 85 074 responded to the third round in June-August 2021. Data were collected through computer-assisted-web interviews (CAWI) or computer-assisted-telephone interviews (CATI). Home self-sampling on dried blood were collected for central Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2) Immunoglobulin G (IgG) antibodies testing during the first and second rounds. Home samples on DBS for detection IgG and neutralizing antibodies were collected in a random sub-sample of 12114 for 1st round of the EPICOV survey (May) and all respondents in November 2020.
Purpose: provide national and regional estimate of sero-prevalence of SARS-CoV-2 infection and to analyze relations between living conditions and the dynamics of the epidemic.
Additional questions: possible to add questions depending on respective agenda of EPICOV and ORCHESTRA. NB: multi-center is not adequate for our study. Consider it non applicable. |